NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cardio Diagnostics Holdings, Inc. (CDIO) Stock Analysis

Cardio Diagnostics Holdings, Inc. (CDIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CDIO

$1.86

+$0.03 (+1.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDIO with… →

CDIO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.85
Previous Close
$1.83
Day's Range
1.82–1.86
52-Week Range
0.97–7.91
Volume
10.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.23
Valuation
Market Cap
$5.50M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
380.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.95
Financials (FY)
Revenue (FY)
$14.83K−57.51%
Net Income (FY)
−$6.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.96M
1-Year Return
−49.57%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
59.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CDIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−31.37%
2025−90.15%
2024−63.17%
2023+134.91%
2022−89.21%

As of September 4, 2026.

CDIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.83K−$6.50M−43832.5%
2024$34.89K−$8.38M−24028.2%
2023$17.07K−$8.38M−49087.8%
2022$950.00−$4.66M−490630.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.83K—−$6.48M−$6.50M−43832.5%
2024$34.89K—−$8.37M−$8.38M−24028.2%
2023$17.07K—−$7.24M−$8.38M−49087.8%
2022$950.00—−$4.55M−$4.66M−490630.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CDIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricCDIOBiotechnology medianvs median
P/S ratio380.9415.2625.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cardio Diagnostics Holdings, Inc. (CDIO) carries a market capitalisation of $5.50M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 15 employees.

The 52-week range on file runs from $0.97 to $7.91. CDIO last closed at $1.86 on September 4, 2026. That is +$0.03 (+1.64%) against the previous close. The latest close sits 91.75% above that 52-week low.

Financial Health

In fiscal 2025, Cardio Diagnostics Holdings, Inc. reported revenue of $14.83K. That is −57.51% against the prior fiscal year, when revenue was $34.89K. The same year closed with a net loss of $6.50M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.95.

Across the 4 fiscal years on file, revenue moves from $950.00 in 2022 to $14.83K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 380.94. On price-to-sales that is 25 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.23. Annualized volatility over the trailing 4 years is 197.31%. The trailing one-year price return is −49.57%. Measured over 3 years, that is −51.40% a year compounded.

Growth & Income

No dividend is on file for CDIO.

2026 is still running; the price is −31.37% year to date. The strongest complete calendar year on file is 2023 at +134.91%; the weakest is 2025 at −90.15%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Cardio Diagnostics Holdings, Inc. (CDIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cardio Diagnostics Holdings, Inc. CDIO $5.50M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cardio Diagnostics Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Visit website →